Xenon Pharmaceuticals stock falls 30.69 percent as trial pause hits

Published on 09/22/2026 at 21:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xenon Pharmaceuticals stock closed at USD 39.75 on September 18, 2026, after a 30.69 percent drop. Wedbush cut its target to USD 55.

XENE, CA98420N1050, Illustration mit AI erstellt.

Xenon Pharmaceuticals Inc. (CA98420N1050) stock closed at USD 39.75 on Nasdaq on September 18, 2026, down USD 17.60, or 30.69 percent, according to the latest quoted market data. The selloff followed a clinical setback involving azetukalner, the company's lead investigational medicine.

Trial recruitment pause drives the selloff

As TheStreet reported on September 21, 2026, Xenon temporarily halted recruitment of additional patients in late-stage depression trials after neuropsychiatric side effects appeared in patients receiving azetukalner. The report said the stock fell as much as 30 percent on September 18, while the epilepsy program continued.

A separate September 22, 2026 report from WallStreetZen said enrollment was paused in depression and bipolar trials after confusion, coordination problems and a small number of psychosis cases were observed. The quantified comparison is stark: the shares lost more than 25 percent after the trial update, while the epilepsy program remained active.

Analyst target falls to USD 55

Wedbush reduced its price target from USD 71.00 to USD 55.00 and maintained an Outperform rating in a research note dated September 18, 2026, according to Ground News. The USD 16 reduction represents a 22.54 percent cut from the previous target and shows how the clinical risk changed the near-term valuation framework.

Bloom Burton also lowered its target from USD 74.00 to USD 71.00 while retaining a Buy rating, according to a September 22, 2026 report. The revised targets remain above the September 18 closing price, but the wide gap between the cuts illustrates the uncertainty around azetukalner's development path.

Stock trades near its yearly low

Market data show a 52-week range of USD 35.97 to USD 72.66, placing the September 18 close of USD 39.75 USD 3.78 above the low and USD 32.91 below the high. The same snapshot lists market capitalization at USD 3.84 billion and volume at 17.88 million shares, compared with average volume of 648,273 shares.

For investors, the key distinction is between the paused psychiatric studies and the continuing epilepsy program. The September 18 price reaction, the 30.69 percent daily decline and the 22.54 percent Wedbush target reduction all quantify how quickly the market repriced the lead program's risk.

Xenon Pharmaceuticals stock remains volatile

Xenon Pharmaceuticals stock closed at USD 39.75 on Nasdaq on September 18, 2026. The stock remains within USD 3.78 of its 52-week low of USD 35.97, while the company retains an active epilepsy development program.